Opioids For Pediatric Cough: UCB Seeks Limits, Pressuring Other Sponsors

UCB will make case for limiting use of Tussionex, its hydrocodone-containing antitussive, to patients 18 years and older at US FDA Pediatric Advisory Committee meeting, where panelists will consider the benefit/risk profile for all currently marketed opioid-containing cough treatments when used in children.